Endocrinology, Vol 132, 823-831, Copyright © 1993 by Endocrine Society

ARTICLES

Parathyroid hormone is more effective than estrogen or bisphosphonates for restoration of lost bone mass in ovariectomized rats

TJ Wronski, CF Yen, H Qi and LM Dann
Department of Physiological Sciences, College of Veterinary Medicine, University of Florida, Gainesville 32610.

The study was designed to compare the therapeutic efficacy of estrogen, the bisphosphonate risedronate (NE-58095), and PTH for restoration of lost bone mass in osteopenic, ovariectomized (OVX) rats. In addition, the skeletal effects of these single treatments were compared to those of concurrent treatments with PTH + estrogen or PTH + NE-58095. OVX rats were untreated for the first 4 weeks postovariectomy to allow for the development of moderate tibial osteopenia. These animals were then subjected to the various treatments for periods of 5, 10, and 15 weeks. Their proximal tibiae were processed undecalcified for quantitative bone histomorphometry. Treatment of osteopenic OVX rats with estrogen or NE-58095 alone depressed bone turnover and prevented additional cancellous bone loss from occurring during the treatment period. However, these therapeutic agents failed to restore lost bone in OVX rats to control levels. In contrast, OVX rats treated with PTH alone exhibited a marked stimulation of bone formation which resulted in augmentation of cancellous bone mass to a level 2-fold greater than that of vehicle-treated control rats. Concurrent treatment of OVX rats with PTH + estrogen as well as PTH + NE-58095 also effectively reversed cancellous osteopenia in OVX rats, but did not appear to be more beneficial to the estrogen-deplete skeleton than treatment with PTH alone. The results indicate that PTH is a powerful stimulator of bone formation and completely restores lost cancellous bone in osteopenic OVX rats. Furthermore, the bone anabolic effects of PTH are much more pronounced than those of estrogen or bisphosphonates. These findings in an animal model of estrogen depletion provide support for PTH as a potentially effective treatment for oophorectomized and postmenopausal women with established osteoporosis.

This article has been cited by other articles:

				T. Kawano, N. Troiano, D. J. Adams, J. Jun Wu, B.-h. Sun, and K. Insogna The Anabolic Response to Parathyroid Hormone Is Augmented in Rac2 Knockout Mice Endocrinology, August 1, 2008; 149(8): 4009 - 4015. [Abstract] [Full Text] [PDF]

				Y. Nakamura, K. Hayashi, S. Abu-Ali, M. Naito, and A. Fotovati Effect of Preoperative Combined Treatment with Alendronate and Calcitriol on Fixation of Hydroxyapatite-Coated Implants in Ovariectomized Rats J. Bone Joint Surg. Am., April 1, 2008; 90(4): 824 - 832. [Abstract] [Full Text] [PDF]

				J. S. Finkelstein, A. Hayes, J. L. Hunzelman, J. J. Wyland, H. Lee, and R. M. Neer The Effects of Parathyroid Hormone, Alendronate, or Both in Men with Osteoporosis N. Engl. J. Med., September 25, 2003; 349(13): 1216 - 1226. [Abstract] [Full Text] [PDF]

				Y. L. Ma, H. U. Bryant, Q. Zeng, A. Schmidt, J. Hoover, H. W. Cole, W. Yao, W. S. S. Jee, and M. Sato New Bone Formation with Teriparatide [Human Parathyroid Hormone-(1-34)] Is Not Retarded by Long-Term Pretreatment with Alendronate, Estrogen, or Raloxifene in Ovariectomized Rats Endocrinology, May 1, 2003; 144(5): 2008 - 2015. [Abstract] [Full Text] [PDF]

				P. J. Kostenuik, C. Capparelli, S. Morony, S. Adamu, G. Shimamoto, V. Shen, D. L. Lacey, and C. R. Dunstan OPG and PTH-(1-34) Have Additive Effects on Bone Density and Mechanical Strength in Osteopenic Ovariectomized Rats Endocrinology, October 1, 2001; 142(10): 4295 - 4304. [Abstract] [Full Text] [PDF]

				K. Yokogawa, K. Miya, T. Sekido, Y. Higashi, M. Nomura, R. Fujisawa, K. Morito, Y. Masamune, Y. Waki, S. Kasugai, et al. Selective Delivery of Estradiol to Bone by Aspartic Acid Oligopeptide and Its Effects on Ovariectomized Mice Endocrinology, March 1, 2001; 142(3): 1228 - 1233. [Abstract] [Full Text] [PDF]

				S. Takahara, T. Morohashi, T. Sano, A. Ohta, S. Yamada, and R. Sasa Fructooligosaccharide Consumption Enhances Femoral Bone Volume and Mineral Concentrations in Rats J. Nutr., July 1, 2000; 130(7): 1792 - 1795. [Abstract] [Full Text]

				J. S. Finkelstein and A. L. Arnold Increases in Bone Mineral Density after Discontinuation of Daily Human Parathyroid Hormone and Gonadotropin-Releasing Hormone Analog Administration in Women with Endometriosis J. Clin. Endocrinol. Metab., April 1, 1999; 84(4): 1214 - 1219. [Abstract] [Full Text]

				A. E. Adams, A. Bisello, M. Chorev, M. Rosenblatt, and L. J. Suva Arginine 186 in the Extracellular N-Terminal Region of the Human Parathyroid Hormone 1 Receptor Is Essential for Contact with Position 13 of the Hormone Mol. Endocrinol., November 1, 1998; 12(11): 1673 - 1683. [Abstract] [Full Text]

				R. T. Turner, G. L. Evans, J. M. Cavolina, B. Halloran, and E. Morey-Holton Programmed Administration of Parathyroid Hormone Increases Bone Formation and Reduces Bone Loss in Hindlimb-Unloaded Ovariectomized Rats Endocrinology, October 1, 1998; 139(10): 4086 - 4091. [Abstract] [Full Text] [PDF]

				J. S. Finkelstein, A. Klibanski, A. L. Arnold, T. L. Toth, M. D. Hornstein, and R. M. Neer Prevention of Estrogen Deficiency-Related Bone Loss With Human Parathyroid Hormone-(1-34): A Randomized Controlled Trial JAMA, September 23, 1998; 280(12): 1067 - 1073. [Abstract] [Full Text] [PDF]

				J. W. M. Chow, S. Fox, C. J. Jagger, and T. J. Chambers Role for parathyroid hormone in mechanical responsiveness of rat bone Am J Physiol Endocrinol Metab, January 1, 1998; 274(1): E146 - E154. [Abstract] [Full Text] [PDF]

				H. Dobnig and R. T. Turner The Effects of Programmed Administration of Human Parathyroid Hormone Fragment (1-34) on Bone Histomorphometry and Serum Chemistry in Rats Endocrinology, November 1, 1997; 138(11): 4607 - 4612. [Abstract] [Full Text] [PDF]

				M. Sato, G. Q. Zeng, and C. H. Turner Biosynthetic Human Parathyroid Hormone (1-34) Effects on Bone Quality in Aged Ovariectomized Rats Endocrinology, October 1, 1997; 138(10): 4330 - 4337. [Abstract] [Full Text] [PDF]

				T. L. McCarthy, C. Ji, H. Shu, S. Casinghino, K. Crothers, P. Rotwein, and M. Centrella 17beta -Estradiol Potently Suppresses cAMP-induced Insulin-like Growth Factor-I Gene Activation in Primary Rat Osteoblast Cultures J. Biol. Chem., July 18, 1997; 272(29): 18132 - 18139. [Abstract] [Full Text] [PDF]